Abstract: Objective To observe the efficacy of sorafenib in the treatment of advanced primary liver cancer. Methods Nineteen patients with advanced primary liver cancer were treated by sorafenib at a dose of 400mg twice daily until the occurrence of intolerable toxicity or death. Results Partial response was obtained in one（5.3%）,stable disease in 10（52.6%）,and progressed disease in 8（42.1%）,and serum alpha fetoprotein decreased in 42.9%（6/14）of patients three months after the regimen;sixteen patients（84.2%） died,and three survived still taking sorafenib at eight month follow-up; sixteen （84.2%）got hand and foot numb,seven （36.8%）got rash and alopecia,ten had blood hypertension, fifteen （78.9%）had gastrointestinal symptoms,two （10.5%） went arrest of bone marrow,and eight （42.1%）had diarrhea. Conclusion Sorafenib is effective and safe in treatment of patients with advanced primary liver cancer. The quality of life in those patients is stable during the administration of sorafenib.

Key words: Primary liver cancer, Advanced, Sorafenib, Efficacy, Side effects